Lin K.K et al. showed that in BRCA1- and BRCA2-mutated ovarian cancer cell lines, after treatment with cisplatin or PARP inhibitors, a protein in the mutated allele was restored, leading to platinum- and PARPi-resistance in these cells [60]. This evidence concerns the gene BRCA1 and ovarian cancer.